Regeneron Pharmaceuticals (REGN)

Regeneron’s ophthalmology franchise includes Eylea and Eylea HD, treatments used for wet age-related macular degeneration and other retinal diseases. These products have been central to the company’s revenue base and are marketed through a major collaboration with Bayer outside the United States. In immunology, Regeneron co-develops and commercializes Dupixent with Sanofi. Dupixent is used across several type 2 inflammatory diseases and is one of the most important products in the company’s portfolio.

The company also markets or partners on products such as Praluent for lowering LDL cholesterol, Libtayo in cancer treatment, Kevzara for rheumatoid arthritis, and Lynozyfic for multiple myeloma. Its pipeline includes additional antibody-based medicines and other biologic candidates, reflecting a strategy of expanding approved drugs into new indications while advancing new therapies from its research engine.

Regeneron competes in markets where innovation, clinical data, patent protection, payer access, and physician adoption are critical. Investors typically watch the durability of the Eylea franchise, growth from Dupixent, progress in oncology and hematology, and the company’s ability to replenish its pipeline as products mature. Its combination of profitable marketed drugs and substantial research capacity makes it a significant name in the global biotech sector.